CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: NK/Ly lymphoma</title> <meta name="description" content="Search results for: NK/Ly lymphoma"> <meta name="keywords" content="NK/Ly lymphoma"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="NK/Ly lymphoma" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="NK/Ly lymphoma"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 58</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: NK/Ly lymphoma</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">58</span> Plasmablastic Lymphoma a New Entity in Patients with HIV Infections</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rojith%20K.%20Balakrishnan">Rojith K. Balakrishnan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Plasmablastic lymphoma (PBL) is an uncommon, recently described B-cell derived lymphoma that is most commonly seen in patients with Human Immunodeficiency Virus (HIV) infection. Here we report a case of PBL in a 35 year old man with HIV who presented with multiple subcutaneous swellings all over the body and oral mucosal lesions.The biopsy report was suggestive of Diffuse Large B Cell Lymphoma. Immunohistochemistry was done which showed, lymphoma cells, positive for MUM1, CD 138, and VS 38. The proliferation index (MIB) was 95%. Final report was consistent with the diagnosis of Plasmablastic Lymphoma. The lesion completely regressed after treatment with systemic chemotherapy. Up to date, only a few cases of plasmablastic lymphoma have been reported from India. Increased frequency of this lymphoma in HIV patients and rarity of the tumour, along with rapid response of the same to chemotherapy, make this case a unique one. Hence the knowledge about this new entity is important for clinicians who deal with HIV patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=human%20immunodeficiency%20virus%20%28HIV%29" title="human immunodeficiency virus (HIV)">human immunodeficiency virus (HIV)</a>, <a href="https://publications.waset.org/abstracts/search?q=oral%20cavity%20lesion" title=" oral cavity lesion"> oral cavity lesion</a>, <a href="https://publications.waset.org/abstracts/search?q=plasmablastic%20lymphoma" title=" plasmablastic lymphoma"> plasmablastic lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=subcutaneous%20swelling" title=" subcutaneous swelling"> subcutaneous swelling</a> </p> <a href="https://publications.waset.org/abstracts/28672/plasmablastic-lymphoma-a-new-entity-in-patients-with-hiv-infections" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/28672.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">274</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">57</span> Study of Non-hodgkin’s Lymphoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Zidani%20Abla">Zidani Abla</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lymphoma is a common type of cancer that affects the lymphatic system, including the lymph nodes, spleen and other associated organs. There are two main types of lymphoma: Hodgkin's lymphoma and non-Hodgkin's lymphoma. The epidemiological, clinical and biological features of lymphoma are poorly studied in Algeria. The main objective of our study is to investigate the epidemiological, clinical, paraclinical, etiological, evolutionary and biological characteristics of non-Hodgkin's lymphoma (NHL) in the hematology department of the University Hospital Center (HUC) of Batna. This is a study of 10 patients diagnosed at Batna University Hospital. 70% were male and 30% female (sex ratio M/F= 2.33). Median age was 51.7 years. Pain, especially abdominal pain, was the main reason for consultation. Stage IV predominated (40%), followed by stage III (20%). Abdominal adenopathies (34%) were the most abundant. Secondary hepatic localization was predominant. Large B-cell NHL predominated, accounting for 60% of cases, followed by small B-cell NHL (30%). Serology for hepatitis B and C, and human immunodeficiency virus (HIV) was negative. Biologically, a predominance of hyperleukocytosis, polynuclear neutrophilic leukocytosis, lymphopenia and hypoalbuminemia were present in the majority of cases. In summary, our results remain to be compared with other works for other periods and other regions in order to generalize lymphoma percentages for the entire Algerian population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=non%20Hodgkin%27s%20lymphoma" title="non Hodgkin's lymphoma">non Hodgkin's lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=epidemiology" title=" epidemiology"> epidemiology</a>, <a href="https://publications.waset.org/abstracts/search?q=clinic" title=" clinic"> clinic</a>, <a href="https://publications.waset.org/abstracts/search?q=biology" title=" biology"> biology</a> </p> <a href="https://publications.waset.org/abstracts/188890/study-of-non-hodgkins-lymphoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/188890.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">28</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">56</span> The Clinical and Survival Differences between Primary B-Cell and T/NK-Cell Non-Hodgkin Lymphomas in the Nasopharynx, Nasal Cavity, and Nasal Sinus: A Population-Based Study of 3839 Cases in the Seer Database</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jiajia%20Peng">Jiajia Peng</a>, <a href="https://publications.waset.org/abstracts/search?q=Danni%20Cheng"> Danni Cheng</a>, <a href="https://publications.waset.org/abstracts/search?q=Jianqing%20Qiu"> Jianqing Qiu</a>, <a href="https://publications.waset.org/abstracts/search?q=Yufang%20Rao"> Yufang Rao</a>, <a href="https://publications.waset.org/abstracts/search?q=Minzi%20Mao"> Minzi Mao</a>, <a href="https://publications.waset.org/abstracts/search?q=Ke%20Qiu"> Ke Qiu</a>, <a href="https://publications.waset.org/abstracts/search?q=Junhong%20Li"> Junhong Li</a>, <a href="https://publications.waset.org/abstracts/search?q=Fei%20Chen"> Fei Chen</a>, <a href="https://publications.waset.org/abstracts/search?q=Feng%20Liu"> Feng Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=Jun%20Liu"> Jun Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=Xiaosong%20Mu"> Xiaosong Mu</a>, <a href="https://publications.waset.org/abstracts/search?q=Wenxin%20Yu"> Wenxin Yu</a>, <a href="https://publications.waset.org/abstracts/search?q=Wei%20Zhang"> Wei Zhang</a>, <a href="https://publications.waset.org/abstracts/search?q=Wei%20Xu"> Wei Xu</a>, <a href="https://publications.waset.org/abstracts/search?q=Yu%20Zhao"> Yu Zhao</a>, <a href="https://publications.waset.org/abstracts/search?q=Jianjun%20Ren"> Jianjun Ren</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Currently, primary B-cell non-Hodgkin lymphoma (B-NHL) and T/NK-cell non-Hodgkin lymphoma (NKT-NHL) originated from the nasal cavity (NC), nasopharynx (NP) and nasal sinus (NS) distinguished unclearly in the clinic. Objective: We sought to compare the clinical and survival differences of B-NHL and NKT-NHL that occurred in NC, NP, and NS, respectively. Methods: Retrospective data of patients diagnosed with nasal cavity lymphoma (NCL), nasopharyngeal lymphoma (NPL), and nasal sinus lymphoma (NSL) between 1975 and 2017 from the Surveillance, Epidemiology, and End Results (SEER) database were collected. We identified the B/NKT-NHL patients based on the histological type and performed univariate, multivariate, and Kaplan-Meier analyses to investigate the survival rates. Results: Of the identified 3,101 B-NHL and 738 NKT-NHL patients, those with B-NHL in NP were the majority (43%) and had better cancer-specific survival than those in NC and NS from 2010 to 2017 (5-year-CSS, NC vs. NP vs. NS: 81% vs. 83% vs. 82%). In contrast, most of the NKT-NHL originated from NC (68%) and had the highest CSS rate in the recent seven years (2010-2017, 5-year-CSS: 63%). Additionally, the survival outcomes of patients with NKT-NHL-NP (HR: 1.34, 95% CI: 0.62-2.89, P=0.460) who had received surgery were much worse than those of patients with NKT-NHL-NC (HR: 1.07, 95% CI: 0.75-1.52, P=0.710) and NKT-NHL-NS (HR: 1.11, 95% CI: 0.59-2.07, P=0.740). NKT-NHL-NS patients who had radiation performed (HR: 0.38, 95% CI: 0.19-0.73, P=0.004) showed the highest survival rates, while chemotherapy performed (HR: 1.01, 95% CI: 0.43-2.37, P=0.980) presented opposite results. Conclusions: Although B-NHL and NKT-NHL originating from NC, NP and NS had similar anatomical locations, their clinical characteristics, treatment therapies, and prognoses were different in this study. Our findings may suggest that B-NHL and NKT-NHL in NC, NP, and NS should be treated as different diseases in the clinic. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nasopharyngeal%20lymphoma" title="nasopharyngeal lymphoma">nasopharyngeal lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=nasal%20cavity%20lymphoma" title=" nasal cavity lymphoma"> nasal cavity lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=nasal%20sinus%20lymphoma" title=" nasal sinus lymphoma"> nasal sinus lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=B-cell%20non-Hodgkin%20lymphoma" title=" B-cell non-Hodgkin lymphoma"> B-cell non-Hodgkin lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=T%2FNK-cell%20non-Hodgkin%20lymphoma" title=" T/NK-cell non-Hodgkin lymphoma"> T/NK-cell non-Hodgkin lymphoma</a> </p> <a href="https://publications.waset.org/abstracts/144875/the-clinical-and-survival-differences-between-primary-b-cell-and-tnk-cell-non-hodgkin-lymphomas-in-the-nasopharynx-nasal-cavity-and-nasal-sinus-a-population-based-study-of-3839-cases-in-the-seer-database" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/144875.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">184</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">55</span> Non-AIDS Related Multiple Brain and Orbital Lymphoma Mimicking Meningioma: A Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Eghosa%20Morgan">Eghosa Morgan</a>, <a href="https://publications.waset.org/abstracts/search?q=Bourtarbouch%20Mahjouba"> Bourtarbouch Mahjouba</a>, <a href="https://publications.waset.org/abstracts/search?q=Heida%20El%20Ouahabi"> Heida El Ouahabi</a>, <a href="https://publications.waset.org/abstracts/search?q=Poluyi%20Edward"> Poluyi Edward</a>, <a href="https://publications.waset.org/abstracts/search?q=Diawarra%20Seylan"> Diawarra Seylan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Non-AIDS lymphoma, a type of primary central nervous system (CNS) lymphoma is an uncommon aggressive infiltrative malignant tumour involving several sites in the central nervous system, such as the periventricular region and leptomeninges. In this article, the authors presented a 26-year old man with painless progressive right exophthalmos and scalp swelling with no symptoms and signs of intracranial hypertension and hyperthyroidism. Magnetic resonance imaging (MRI) done revealed isointense masses with brilliant homogenous enhancement on contrast administration resembling a meningioma, with a dura tail – like attachment as seen in meningioma. He had surgery for the right orbital tumour and histopathological diagnosis confirmed our suspicion of lymphoma (B type). Steroid was given in the post-operative period which led to significant regression of the tumours, hence its description as ‘vanishing tumour’. He is presently receiving methotrexate-based chemotherapy and subsequently planned for radiotherapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=central%20nervous%20system%20%28CNS%29" title="central nervous system (CNS)">central nervous system (CNS)</a>, <a href="https://publications.waset.org/abstracts/search?q=meningioma" title=" meningioma"> meningioma</a>, <a href="https://publications.waset.org/abstracts/search?q=non-aids%20lymphoma" title=" non-aids lymphoma"> non-aids lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=orbital" title=" orbital"> orbital</a> </p> <a href="https://publications.waset.org/abstracts/153811/non-aids-related-multiple-brain-and-orbital-lymphoma-mimicking-meningioma-a-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153811.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">91</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">54</span> Incidence of Lymphoma and Gonorrhea Infection: A Retrospective Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Diya%20Kohli">Diya Kohli</a>, <a href="https://publications.waset.org/abstracts/search?q=Amalia%20Ardeljan"> Amalia Ardeljan</a>, <a href="https://publications.waset.org/abstracts/search?q=Lexi%20Frankel"> Lexi Frankel</a>, <a href="https://publications.waset.org/abstracts/search?q=Jose%20Garcia"> Jose Garcia</a>, <a href="https://publications.waset.org/abstracts/search?q=Lokesh%20Manjani"> Lokesh Manjani</a>, <a href="https://publications.waset.org/abstracts/search?q=Omar%20Rashid"> Omar Rashid</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Gonorrhea is the second most common sexually transmitted disease (STDs) in the United States of America. Gonorrhea affects the urethra, rectum, or throat and the cervix in females. Lymphoma is a cancer of the immune network called the lymphatic system that includes the lymph nodes/glands, spleen, thymus gland, and bone marrow. Lymphoma can affect many organs in the body. When a lymphocyte develops a genetic mutation, it signals other cells into rapid proliferation that causes many mutated lymphocytes. Multiple studies have explored the incidence of cancer in people infected with STDs such as Gonorrhea. For instance, the studies conducted by Wang Y-C and Co., as well as Caini, S and Co. established a direct co-relationship between Gonorrhea infection and incidence of prostate cancer. We hypothesize that Gonorrhea infection also increases the incidence of Lymphoma in patients. This research study aimed to evaluate the correlation between Gonorrhea infection and the incidence of Lymphoma. The data for the research was provided by a Health Insurance Portability and Accountability Act (HIPAA) compliant national database. This database was utilized to evaluate patients infected with Gonorrhea versus the ones who were not infected to establish a correlation with the prevalence of Lymphoma using ICD-10 and ICD-9 codes. Access to the database was granted by the Holy Cross Health, Fort Lauderdale for academic research. Standard statistical methods were applied throughout. Between January 2010 and December 2019, the query was analyzed and resulted in 254 and 808 patients in both the infected and control group, respectively. The two groups were matched by Age Range and CCI score. The incidence of Lymphoma was 0.998% (254 patients out of 25455) in the Gonorrhea group (patients infected with Gonorrhea that was Lymphoma Positive) compared to 3.174% and 808 patients in the control group (Patients negative for Gonorrhea but with Lymphoma). This was statistically significant by a p-value < 2.210-16 with an OR= 0.431 (95% CI 0.381-0.487). The patients were then matched by antibiotic treatment to avoid treatment bias. The incidence of Lymphoma was 1.215% (82 patients out of 6,748) in the Gonorrhea group compared to 2.949% (199 patients out of 6748) in the control group. This was statistically significant by a p-value <5.410-10 with an OR= 0.468 (95% CI 0.367-0.596). The study shows a statistically significant correlation between Gonorrhea and a reduced incidence of Lymphoma. Further evaluation is recommended to assess the potential of Gonorrhea in reducing Lymphoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=gonorrhea" title="gonorrhea">gonorrhea</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=STDs" title=" STDs"> STDs</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=ICD" title=" ICD"> ICD</a> </p> <a href="https://publications.waset.org/abstracts/140202/incidence-of-lymphoma-and-gonorrhea-infection-a-retrospective-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140202.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">195</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">53</span> The Role Previous Cytomegalovirus Infection in Subsequent Lymphoma Develompment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Amalia%20Ardeljan">Amalia Ardeljan</a>, <a href="https://publications.waset.org/abstracts/search?q=Lexi%20Frankel"> Lexi Frankel</a>, <a href="https://publications.waset.org/abstracts/search?q=Divesh%20Manjani"> Divesh Manjani</a>, <a href="https://publications.waset.org/abstracts/search?q=Gabriela%20Santizo"> Gabriela Santizo</a>, <a href="https://publications.waset.org/abstracts/search?q=Maximillian%20Guerra"> Maximillian Guerra</a>, <a href="https://publications.waset.org/abstracts/search?q=Omar%20Rashid"> Omar Rashid</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Cytomegalovirus (CMV) infection is a widespread infection affecting between 60-70% of people in industrialized countries. CMV has been previously correlated with a higher incidence of Hodgkin Lymphoma compared to noninfected persons. Research regarding prior CMV infection and subsequent lymphoma development is still controversial. With limited evidence, further research is needed in order to understand the relationship between previous CMV infection and subsequent lymphoma development. This study assessed the effect of CMV infection and the incidence of lymphoma afterward. Methods: A retrospective cohort study (2010-2019) was conducted through a Health Insurance Portability and Accountability Act (HIPAA) compliant national database and conducted using International Classification of Disease (ICD) 9th,10th codes, and Current Procedural Terminology (CPT) codes. These were used to identify lymphoma diagnosis in a previously CMV infected population. Patients were matched for age range and Charlson Comorbidity Index (CCI). A chi-squared test was used to assess statistical significance. Results: A total number of 14,303 patients was obtained in the CMV infected group as well as in the control population (matched by age range and CCI score). Subsequent lymphoma development was seen at a rate of 11.44% (1,637) in the CMV group and 5.74% (822) in the control group, respectively. The difference was statistically significant by p= 2.2x10-16, odds ratio = 2.696 (95% CI 2.483- 2.927). In an attempt to stratify the population by antiviral medication exposure, the outcomes were limited by the decreased number of members exposed to antiviral medication in the control population. Conclusion: This study shows a statistically significant correlation between prior CMV infection and an increased incidence of lymphoma afterward. Further exploration is needed to identify the potential carcinogenic mechanism of CMV and whether the results are attributed to a confounding bias. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cytomegalovirus" title="cytomegalovirus">cytomegalovirus</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=microbiology" title=" microbiology"> microbiology</a> </p> <a href="https://publications.waset.org/abstracts/140178/the-role-previous-cytomegalovirus-infection-in-subsequent-lymphoma-develompment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140178.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">219</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">52</span> Oxidative Antioxidative Status and DNA Damage Profile Induced by Chemotherapy in Algerian Children with Lymphoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Assia%20Galleze">Assia Galleze</a>, <a href="https://publications.waset.org/abstracts/search?q=Abdurrahim%20Kocyigit"> Abdurrahim Kocyigit</a>, <a href="https://publications.waset.org/abstracts/search?q=Nacira%20%20Cherif"> Nacira Cherif</a>, <a href="https://publications.waset.org/abstracts/search?q=Nidel%20Benhalilou"> Nidel Benhalilou</a>, <a href="https://publications.waset.org/abstracts/search?q=Nabila%20Attal"> Nabila Attal</a>, <a href="https://publications.waset.org/abstracts/search?q=Chafia%20Touil%20Boukkoffa"> Chafia Touil Boukkoffa</a>, <a href="https://publications.waset.org/abstracts/search?q=Rachida%20Raache"> Rachida Raache</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction and aims: Chemotherapeutic agents used to inhibit cell division and reduce tumor growth, increase reactive oxygen species levels, which contributes to their genotoxicity [1]. The comet assay is an inexpensive and rapid method to detect the damage at cellular levels and has been used in various cancer populations undergoing chemotherapy [2,3]. The present study aim to assess the oxidative stress and the genotoxicity induced by chemotherapy by the determination of plasma malondialdehyde (MDA) level, protein carbonyl (PC) content, superoxide dismutase (SOD) activity and lymphocyte DNA damage in Algerian children with lymphoma. Materials and Methods: For our study, we selected thirty children with lymphoma treated in university hospital of Beni Messous, Algeria, and fifty unrelated subjects as controls, after obtaining the informed consent in accordance with the Declaration of Helsinki (1964). Plasma levels of MDA, PC and SOD activity were spectrophotometrically measured, while DNA damage was assessed by alkaline comet assay in peripheral blood leukocytes. Results and Discussion: Plasma MDA, PC levels and lymphocyte DNA damage, were found to be significantly higher in lymphoma patients than in controls (p < 0.001). Whereas, SOD activity in lymphoma patients was significantly lower than in healthy controls (p < 0.001). There were significant positive correlations between DNA damage, MDA and PC in patients (r = 0.96, p < 0.001, r = 0.97, p < 0.001, respectively), and negative correlation with SOD (r = 0.87, p < 0.01). Conclusion and Perspective: Our results indicated that, leukocytes DNA damage and oxidative stress were significantly higher in lymphoma patients, suggesting that the direct effect of chemotherapy and the alteration of the redox balance may influence oxidative/antioxidative status. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chemotherapy" title="chemotherapy">chemotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=comet%20assay" title=" comet assay"> comet assay</a>, <a href="https://publications.waset.org/abstracts/search?q=DNA%20damage" title=" DNA damage"> DNA damage</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a> </p> <a href="https://publications.waset.org/abstracts/124329/oxidative-antioxidative-status-and-dna-damage-profile-induced-by-chemotherapy-in-algerian-children-with-lymphoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/124329.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">137</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">51</span> Lymphomas as Estrogen-Regulated Cancers</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20S.%20Hasni">M. S. Hasni</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Guan"> J. Guan</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Yakimchuk"> K. Yakimchuk</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Berglund"> M. Berglund</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20Sander"> B. Sander</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20Enblad"> G. Enblad</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20M.%20Amini"> R. M. Amini</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Okret"> S. Okret</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lymphomas are generally not considered as endocrine-related cancers. However, most lymphoid malignancies show gender differences in incidence and show prognosis with males being more affected. Furthermore, some epidemiological data indicate a protective role of estrogens against Non-Hodgkin lymphomas. Recent studies have demonstrated estrogen receptor β (ERβ) to be the major ER expressed in normal and malignant cells of lymphoid origin. We have analyzed the effects of estradiol and selective ERα and ERβ agonists on lymphoma growth in culture and in vivo. Treating lymphoma cells with estradiol or ERα selective agonist had minor or no effect on cell growth while selective ERβ agonist treatment showed an antiproliferative effect. When grafting mice with murine T lymphoma cells, male mice developed larger tumors compared to female mice, a difference that was abolished following ovariectomy, demonstrating estrogen-dependent growth in vivo. When subcutaneously grafting lymphoma cells to mice, so far growth of all tested human B lymphoma tumors (Raji and Ramos Burkitt lymphoma, SU.DHL4 (GC) and U2932 (ABC) DLBCL, Granta-519, Maver1 and Z138 MCL cells), were reduced following treatment with ERβ selective agonist (ref. 2 and unpublished). Moreover, the number and size of liver foci of disseminating Raji cells was reduced. We have identified target genes and mechanism that could explain the above effects of ERβ agonists. This included effects on angio and lymphangiogenesis. Now we have further analyzed effects of ERβ agonists on Ibrutinib-sensitive and -insensitive MCL cells in xenograft experiments as well as ERβ expression in primary lymphoma material (DLBCL). Preliminary statistical analysis has been done correlating ERβ expression to other biomarkers and clinical data. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=lymphomas" title="lymphomas">lymphomas</a>, <a href="https://publications.waset.org/abstracts/search?q=estrogen%20receptors" title=" estrogen receptors"> estrogen receptors</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20foci" title=" liver foci"> liver foci</a> </p> <a href="https://publications.waset.org/abstracts/17116/lymphomas-as-estrogen-regulated-cancers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17116.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">411</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">50</span> Granulomatous Mycoses Fungoides: A Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Girum%20Tedla%20Assefa">Girum Tedla Assefa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Granulomatous mycosis fungoides is an extremely rare type of cutaneous T-cell lymphoma (<55 cases reported worldwide). Case report: A 36-year-old female presented with soft tissue atrophy of right lower limb (dermis + hypodermis) of 22 years and plaques over trunk of 3 years duration. Histological examination of a biopsy taken from the atrophied tissue showed a granulomatous reaction with epidermotropic atypical lymphocytes. However, in other areas there were only ﬁndings of conventional MF without granuloma. Conclusion: The diagnosis of a granulomatous mycosis fungoides depends exclusively on the histological demonstration of granulomas. Distinct clinical characteristics are not present. This case highlights the importance of thorough investigation of lipoatrophic skin changes in the adult to exclude underlying causes, including MF. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cutaneous%20lymphoma" title="cutaneous lymphoma">cutaneous lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=granulomatous%20skin%20lymphoma" title=" granulomatous skin lymphoma"> granulomatous skin lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=mycoses%20fungoides" title=" mycoses fungoides"> mycoses fungoides</a>, <a href="https://publications.waset.org/abstracts/search?q=skin%20atrophy" title=" skin atrophy"> skin atrophy</a> </p> <a href="https://publications.waset.org/abstracts/34215/granulomatous-mycoses-fungoides-a-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34215.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">371</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">49</span> Principle Component Analysis on Colon Cancer Detection</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=N.%20K.%20Caecar%20Pratiwi">N. K. Caecar Pratiwi</a>, <a href="https://publications.waset.org/abstracts/search?q=Yunendah%20Nur%20Fuadah"> Yunendah Nur Fuadah</a>, <a href="https://publications.waset.org/abstracts/search?q=Rita%20Magdalena"> Rita Magdalena</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20D.%20Atmaja"> R. D. Atmaja</a>, <a href="https://publications.waset.org/abstracts/search?q=Sofia%20Saidah"> Sofia Saidah</a>, <a href="https://publications.waset.org/abstracts/search?q=Ocky%20Tiaramukti"> Ocky Tiaramukti</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Colon cancer or colorectal cancer is a type of cancer that attacks the last part of the human digestive system. Lymphoma and carcinoma are types of cancer that attack human’s colon. Colon cancer causes deaths about half a million people every year. In Indonesia, colon cancer is the third largest cancer case for women and second in men. Unhealthy lifestyles such as minimum consumption of fiber, rarely exercising and lack of awareness for early detection are factors that cause high cases of colon cancer. The aim of this project is to produce a system that can detect and classify images into type of colon cancer lymphoma, carcinoma, or normal. The designed system used 198 data colon cancer tissue pathology, consist of 66 images for Lymphoma cancer, 66 images for carcinoma cancer and 66 for normal / healthy colon condition. This system will classify colon cancer starting from image preprocessing, feature extraction using Principal Component Analysis (PCA) and classification using K-Nearest Neighbor (K-NN) method. Several stages in preprocessing are resize, convert RGB image to grayscale, edge detection and last, histogram equalization. Tests will be done by trying some K-NN input parameter setting. The result of this project is an image processing system that can detect and classify the type of colon cancer with high accuracy and low computation time. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=carcinoma" title="carcinoma">carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=colorectal%20cancer" title=" colorectal cancer"> colorectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=k-nearest%20neighbor" title=" k-nearest neighbor"> k-nearest neighbor</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=principle%20component%20analysis" title=" principle component analysis"> principle component analysis</a> </p> <a href="https://publications.waset.org/abstracts/105607/principle-component-analysis-on-colon-cancer-detection" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/105607.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">205</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">48</span> A Case of Mantle Cell Lymphoma Presenting With GI Symptoms and Noted to Have Extranodal Involvement of the Stomach and Colon on Presentation</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Saba%20Amreen%20Syeda">Saba Amreen Syeda</a>, <a href="https://publications.waset.org/abstracts/search?q=Summaiah%20Asim"> Summaiah Asim</a>, <a href="https://publications.waset.org/abstracts/search?q=Syeda"> Syeda</a>, <a href="https://publications.waset.org/abstracts/search?q=Hafsa"> Hafsa</a>, <a href="https://publications.waset.org/abstracts/search?q=Essam%20Quraishi"> Essam Quraishi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Mantle Cell Lymphoma (MCL) is a relatively uncommon type of lymphoma that comprises approximately 7 percent of non hodgkin's lymphomas (NHL), Classic MCL presents mostly in lymph nodes and occasionally in extranodal sites. About 26 % of MCL is present primarily in the Gastrointestinal tract. While both the upper GI tract and the lower GI tract could be involved, it is rare to present with concurrent upper and lower GI involvement with MCL. We present the case of a 51-year-old Asian Indian male that presented to our clinic with complaints of chronic diarrhea for the last one year, progressively worsening over the past three months. The Patient also reported black stool as well as bright red blood per rectum. Patient reported severe fatigue on minimal exertion. On a physical exam, the patient was noted to have matted lymphadenopathy in the neck. Patient was noted to be anemic with a hemoglobin to be 8 g/dl. Esophagogastroduodenoscopy and colonoscopy was performed. EGD showed a large 4 cm ulcer in the gastric antrum with thick heaped up edges. There was bleeding on contact. Colonoscopy showed a large 35 mm multilobulated polyp in the ascending colon, which was biopsied. The patient was also noted to have nodular proctitis in the mid rectum. This was localized and extended to about 5 cm. This area was biopsied as well. Biopsies from the stomach, colon, as well as the rectum, returned with findings of mantle cell lymphoma on pathology. Lymphoid cells in the biopsy were stained strongly positive for CD 20, cyclin D1, and CD 5. There was the absence of stain for CD 3 and CD 10. The IHC stain for CD 23 was negative. Biopsies from neck LAD were obtained and were also positive for MCL. The patient was referred to oncology for staging and treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=mantle%20cell%20lymphoma" title="mantle cell lymphoma">mantle cell lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=GI%20bleed" title=" GI bleed"> GI bleed</a>, <a href="https://publications.waset.org/abstracts/search?q=diarrhea" title=" diarrhea"> diarrhea</a>, <a href="https://publications.waset.org/abstracts/search?q=gastric%20ulcer" title=" gastric ulcer"> gastric ulcer</a>, <a href="https://publications.waset.org/abstracts/search?q=colon%20polyp" title=" colon polyp"> colon polyp</a> </p> <a href="https://publications.waset.org/abstracts/157000/a-case-of-mantle-cell-lymphoma-presenting-with-gi-symptoms-and-noted-to-have-extranodal-involvement-of-the-stomach-and-colon-on-presentation" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/157000.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">157</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">47</span> Physiological Normoxia and Cellular Adhesion of Diffuse Large B-Cell Lymphoma Primary Cells: Real-Time PCR and Immunohistochemistry Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kamila%20Du%C5%9B-Szachniewicz">Kamila Duś-Szachniewicz</a>, <a href="https://publications.waset.org/abstracts/search?q=Kinga%20M.%20Walaszek"> Kinga M. Walaszek</a>, <a href="https://publications.waset.org/abstracts/search?q=Pawe%C5%82%20Skiba"> Paweł Skiba</a>, <a href="https://publications.waset.org/abstracts/search?q=Pawe%C5%82%20Ko%C5%82odziej"> Paweł Kołodziej</a>, <a href="https://publications.waset.org/abstracts/search?q=Piotr%20Zi%C3%B3%C5%82kowski"> Piotr Ziółkowski</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cell adhesion is of fundamental importance in the cell communication, signaling, and motility, and its dysfunction occurs prevalently during cancer progression. The knowledge of the molecular and cellular processes involved in abnormalities in cancer cells adhesion has greatly increased, and it has been focused mainly on cellular adhesion molecules (CAMs) and tumor microenvironment. Unfortunately, most of the data regarding CAMs expression relates to study on cells maintained in standard oxygen condition of 21%, while the emerging evidence suggests that culturing cells in ambient air is far from physiological. In fact, oxygen in human tissues ranges from 1 to 11%. The aim of this study was to compare the effects of physiological lymph node normoxia (5% O2), and hyperoxia (21% O2) on the expression of cellular adhesion molecules of primary diffuse large B-cell lymphoma cells (DLBCL) isolated from 10 lymphoma patients. Quantitative RT-PCR and immunohistochemistry were used to confirm the differential expression of several CAMs, including ICAM, CD83, CD81, CD44, depending on the level of oxygen. Our findings also suggest that DLBCL cells maintained at ambient O2 (21%) exhibit reduced growth rate and migration ability compared to the cells growing in normoxia conditions. Taking into account all the observations, we emphasize the need to identify the optimal human cell culture conditions mimicking the physiological aspects of tumor growth and differentiation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adhesion%20molecules" title="adhesion molecules">adhesion molecules</a>, <a href="https://publications.waset.org/abstracts/search?q=diffuse%20large%20B-cell%20lymphoma" title=" diffuse large B-cell lymphoma"> diffuse large B-cell lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=physiological%20normoxia" title=" physiological normoxia"> physiological normoxia</a>, <a href="https://publications.waset.org/abstracts/search?q=quantitative%20RT-PCR" title=" quantitative RT-PCR"> quantitative RT-PCR</a> </p> <a href="https://publications.waset.org/abstracts/58050/physiological-normoxia-and-cellular-adhesion-of-diffuse-large-b-cell-lymphoma-primary-cells-real-time-pcr-and-immunohistochemistry-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/58050.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">278</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">46</span> Finding Bicluster on Gene Expression Data of Lymphoma Based on Singular Value Decomposition and Hierarchical Clustering</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Alhadi%20Bustaman">Alhadi Bustaman</a>, <a href="https://publications.waset.org/abstracts/search?q=Soeganda%20Formalidin"> Soeganda Formalidin</a>, <a href="https://publications.waset.org/abstracts/search?q=Titin%20Siswantining"> Titin Siswantining</a> </p> <p class="card-text"><strong>Abstract:</strong></p> DNA microarray technology is used to analyze thousand gene expression data simultaneously and a very important task for drug development and test, function annotation, and cancer diagnosis. Various clustering methods have been used for analyzing gene expression data. However, when analyzing very large and heterogeneous collections of gene expression data, conventional clustering methods often cannot produce a satisfactory solution. Biclustering algorithm has been used as an alternative approach to identifying structures from gene expression data. In this paper, we introduce a transform technique based on singular value decomposition to identify normalized matrix of gene expression data followed by Mixed-Clustering algorithm and the Lift algorithm, inspired in the node-deletion and node-addition phases proposed by Cheng and Church based on Agglomerative Hierarchical Clustering (AHC). Experimental study on standard datasets demonstrated the effectiveness of the algorithm in gene expression data. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=agglomerative%20hierarchical%20clustering%20%28AHC%29" title="agglomerative hierarchical clustering (AHC)">agglomerative hierarchical clustering (AHC)</a>, <a href="https://publications.waset.org/abstracts/search?q=biclustering" title=" biclustering"> biclustering</a>, <a href="https://publications.waset.org/abstracts/search?q=gene%20expression%20data" title=" gene expression data"> gene expression data</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=singular%20value%20decomposition%20%28SVD%29" title=" singular value decomposition (SVD)"> singular value decomposition (SVD)</a> </p> <a href="https://publications.waset.org/abstracts/72889/finding-bicluster-on-gene-expression-data-of-lymphoma-based-on-singular-value-decomposition-and-hierarchical-clustering" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/72889.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">278</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">45</span> Risk of Mortality and Spectrum of Second Primary Malignancies in Mantle Cell Lymphoma before and after Ibrutinib Approval: A Population-Based Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Karthik%20Chamari">Karthik Chamari</a>, <a href="https://publications.waset.org/abstracts/search?q=Vasudha%20Rudraraju"> Vasudha Rudraraju</a>, <a href="https://publications.waset.org/abstracts/search?q=Gaurav%20Chaudhari"> Gaurav Chaudhari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Mantle cell lymphoma (MCL) is one of the mature B cell non-Hodgkin lymphomas (NHL). The course of MCL is moderately aggressive and variable, and it has median overall survival of 8 to 10 years. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, was approved by the United States (US) Food and Drug Administration in November of 2013 for the treatment of MCL patients who have received at least one prior therapy. In this study, we aimed to evaluate whether there has been a change in survival and patterns of second primary malignancies (SPMs) among the MCL population in the US after ibrutinib approval. Methods: Using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER)-18, we conducted a retrospective study with patients diagnosed with MCL (ICD-0-3 code 9673/3) between 2007 and 2018. We divided patients into two six-year cohorts, pre-ibrutinib approval (2007-2012) and post-ibrutinib approval (2013-2018), and compared relative survival rates (RSRs) and standardized incidence ratios (SIRs) of SPMs between cohorts. Results: We included 9,257 patients diagnosed with MCL between 2007 and 2018 in the SEER-18 survival and SIR registries. Of these, 4,205 (45%) patients were included in the pre-ibrutinib cohort, and 5052 (55%) patients were included in the post-ibrutinib cohort. The median follow-up duration for the pre-ibrutinib cohort was 54 months (range 0 to 143 months), and the post-ibrutinib cohort was 20 months (range 0 to 71 months). There was a significant difference in the five-year RSRs between pre-ibrutinib and post-ibrutinib cohorts (57.5% vs. 62.6%, p < 0.005). Out of the 9,257 patients diagnosed with MCL, 920 developed SPMs. A higher proportion of SPMs occurred in the post-ibrutinib cohort (63%) when compared with the pre-ibrutinib cohort (37%). Non-hematological malignancies comprised most of all SPMs. A higher incidence of non-hematological malignancies occurred in the post-ibrutinib cohort (SIR 1.42, 95% CI 1.29 to 1.56) when compared with the pre-ibrutinib cohort (SIR 1.14, 95% CI 1 to 1.3). There was a statistically significant increase in the incidence of cancers of the respiratory tract (SIR 1.77, 95% CI 1.43 to 2.18), urinary tract (SIR 1.61, 95% CI 1.23 to 2.06) when compared with other non-hematological malignancies in post-ibrutinib cohort. Conclusions: Our study results suggest the relative survival rates have increased since the approval of ibrutinib for mantle cell lymphoma patients. Additionally, for some unclear reasons, the incidence of SPM’s (non-hematological malignancies), mainly cancers of the respiratory tract, urinary tract, have increased in the six years following the approval of ibrutinib. Further studies should be conducted to determine the cause of these findings. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=mantle%20cell%20lymphoma" title="mantle cell lymphoma">mantle cell lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=Ibrutinib" title=" Ibrutinib"> Ibrutinib</a>, <a href="https://publications.waset.org/abstracts/search?q=relative%20survival%20analysis" title=" relative survival analysis"> relative survival analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=secondary%20primary%20cancers" title=" secondary primary cancers"> secondary primary cancers</a> </p> <a href="https://publications.waset.org/abstracts/141117/risk-of-mortality-and-spectrum-of-second-primary-malignancies-in-mantle-cell-lymphoma-before-and-after-ibrutinib-approval-a-population-based-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/141117.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">185</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">44</span> Diagnosis, Treatment, and Prognosis in Cutaneous Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Narrative Review Apropos of a Case</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Laura%20Gleason">Laura Gleason</a>, <a href="https://publications.waset.org/abstracts/search?q=Sahithi%20Talasila"> Sahithi Talasila</a>, <a href="https://publications.waset.org/abstracts/search?q=Lauren%20Banner"> Lauren Banner</a>, <a href="https://publications.waset.org/abstracts/search?q=Ladan%20Afifi"> Ladan Afifi</a>, <a href="https://publications.waset.org/abstracts/search?q=Neda%20Nikbakht"> Neda Nikbakht</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Primary cutaneous anaplastic large cell lymphoma (pcALCL) accounts for 9% of all cutaneous T-cell lymphomas. pcALCL is classically characterized as a solitary papulonodule that often enlarges, ulcerates, and can be locally destructive, but overall exhibits an indolent course with overall 5-year survival estimated to be 90%. Distinguishing pcALCL from systemic ALCL (sALCL) is essential as sALCL confers a poorer prognosis with average 5-year survival being 40-50%. Although extremely rare, there have been several cases of ALK-positive ALCL diagnosed on skin biopsy without evidence of systemic involvement, which poses several challenges in the classification, prognostication, treatment, and follow-up of these patients. Objectives: We present a case of cutaneous ALK-positive ALCL without evidence of systemic involvement, and a narrative review of the literature to further characterize that ALK-positive ALCL limited to the skin is a distinct variant with a unique presentation, history, and prognosis. A 30-year-old woman presented for evaluation of an erythematous-violaceous papule present on her right chest for two months. With the development of multifocal disease and persistent lymphadenopathy, a bone marrow biopsy and lymph node excisional biopsy were performed to assess for systemic disease. Both biopsies were unrevealing. The patient was counseled on pursuing systemic therapy consisting of Brentuximab, Cyclophosphamide, Doxorubicin, and Prednisone given the concern for sALCL. Apropos of the patient we searched for clinically evident, cutaneous ALK-positive ALCL cases, with and without systemic involvement, in the English literature. Risk factors, such as tumor location, number, size, ALK localization, ALK translocations, and recurrence, were evaluated in cases of cutaneous ALK-positive ALCL. The majority of patients with cutaneous ALK-positive ALCL did not progress to systemic disease. The majority of cases that progressed to systemic disease in adults had recurring skin lesions and cytoplasmic localization of ALK. ALK translocations did not influence disease progression. Mean time to disease progression was 16.7 months, and significant mortality (50%) was observed in those cases that progressed to systemic disease. Pediatric cases did not exhibit a trend similar to adult cases. In both the adult and pediatric cases, a subset of cutaneous-limited ALK-positive ALCL were treated with chemotherapy. All cases treated with chemotherapy did not progress to systemic disease. Apropos of an ALK-positive ALCL patient with clinical cutaneous limited disease in the histologic presence of systemic markers, we discussed the literature data, highlighting the crucial issues related to developing a clinical strategy to approach this rare subtype of ALCL. Physicians need to be aware of the overall spectrum of ALCL, including cutaneous limited disease, systemic disease, disease with NPM-ALK translocation, disease with ALK and EMA positivity, and disease with skin recurrence. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anaplastic%20large%20cell%20lymphoma" title="anaplastic large cell lymphoma">anaplastic large cell lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=systemic" title=" systemic"> systemic</a>, <a href="https://publications.waset.org/abstracts/search?q=cutaneous" title=" cutaneous"> cutaneous</a>, <a href="https://publications.waset.org/abstracts/search?q=anaplastic%20lymphoma%20kinase" title=" anaplastic lymphoma kinase"> anaplastic lymphoma kinase</a>, <a href="https://publications.waset.org/abstracts/search?q=ALK" title=" ALK"> ALK</a>, <a href="https://publications.waset.org/abstracts/search?q=ALCL" title=" ALCL"> ALCL</a>, <a href="https://publications.waset.org/abstracts/search?q=sALCL" title=" sALCL"> sALCL</a>, <a href="https://publications.waset.org/abstracts/search?q=pcALCL" title=" pcALCL"> pcALCL</a>, <a href="https://publications.waset.org/abstracts/search?q=cALCL" title=" cALCL"> cALCL</a> </p> <a href="https://publications.waset.org/abstracts/152761/diagnosis-treatment-and-prognosis-in-cutaneous-anaplastic-lymphoma-kinase-positive-anaplastic-large-cell-lymphoma-a-narrative-review-apropos-of-a-case" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/152761.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">83</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">43</span> Differential Infection of Primary Human B-Cells and EBV Positive B-Lymphoma Cell Lines by Recombinant AAV Serotypes </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Elham%20Ahmadi">Elham Ahmadi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehrdad%20Ravanshad"> Mehrdad Ravanshad</a>, <a href="https://publications.waset.org/abstracts/search?q=Joyce%20Fingeroth"> Joyce Fingeroth</a>, <a href="https://publications.waset.org/abstracts/search?q=Mazyar%20Ziyaeyan"> Mazyar Ziyaeyan</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajesh%20Panigrahi"> Rajesh Panigrahi</a>, <a href="https://publications.waset.org/abstracts/search?q=Jun%20Xie"> Jun Xie</a>, <a href="https://publications.waset.org/abstracts/search?q=Gao%20Guangping"> Gao Guangping</a> </p> <p class="card-text"><strong>Abstract:</strong></p> B-cell proliferative disorders often occur among persons that are T-cell compromised. These disorders are primarily EBV+ and can first present with a focal lesion. Direct introduction of oncolytic viruses into localized tumors provides theoretical advantages over chemotherapy and immunotherapy by reducing systemic toxicity, to which the immunocompromised host is most vulnerable. Widely studied as a vehicle for gene therapy, AAV has only rarely been applied to treat cancer. As a prelude to development of a therapeutic vehicle, we assessed the ability of 15 distinct recombinant AAV serotypes (rAAV1, rAAV2, rAAV3b, rAAV4, rAAV5, rAAV6, rAAV6.2, rAAV6TM, rAAV7, rAAV8, rAAVrh8, rAAV9, rAAVrh10, rAAV39, rAAV43) bearing eGFP to infect human B-cell tumor lines compared with primary B-cells in vitro. Enhanced infection of tumor lines by AAV 6.2 was demonstrated by flow cytometry. EBV superinfection of EBV negative B-cell tumor lines increased susceptibility to AAV6.2 infection. As proof of concept, AAV6.2 bearing HSV-1 thymidine kinase in place of eGFP eliminated tumor cells upon exposure to ganciclovir. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=AAV" title="AAV">AAV</a>, <a href="https://publications.waset.org/abstracts/search?q=gene%20therapy" title=" gene therapy"> gene therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=malignancy" title=" malignancy"> malignancy</a>, <a href="https://publications.waset.org/abstracts/search?q=tropism" title=" tropism"> tropism</a> </p> <a href="https://publications.waset.org/abstracts/112865/differential-infection-of-primary-human-b-cells-and-ebv-positive-b-lymphoma-cell-lines-by-recombinant-aav-serotypes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/112865.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">120</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">42</span> Diagnostic Accuracy Of Core Biopsy In Patients Presenting With Axillary Lymphadenopathy And Suspected Non-Breast Malignancy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Monisha%20Edirisooriya">Monisha Edirisooriya</a>, <a href="https://publications.waset.org/abstracts/search?q=Wilma%20Jack"> Wilma Jack</a>, <a href="https://publications.waset.org/abstracts/search?q=Dominique%20Twelves">Dominique Twelves</a>, <a href="https://publications.waset.org/abstracts/search?q=Jennifer%20Royds"> Jennifer Royds</a>, <a href="https://publications.waset.org/abstracts/search?q=Fiona%20Scott"> Fiona Scott</a>, <a href="https://publications.waset.org/abstracts/search?q=Nicola%20Mason"> Nicola Mason</a>, <a href="https://publications.waset.org/abstracts/search?q=Arran%20Turnbull"> Arran Turnbull</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Michael%20Dixon"> J. Michael Dixon</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Excision biopsy has been the investigation of choice for patients presenting with pathological axillary lymphadenopathy without a breast abnormality. Core biopsy of nodes can provide sufficient tissue for diagnosis and has advantages in terms of morbidity and speed of diagnosis. This study evaluates the diagnostic accuracy of core biopsy in patients presenting with axillary lymphadenopathy. Methods: Between 2009 and 2019, 165 patients referred to the Edinburgh Breast Unit had a total of 179 axillary lymph node core biopsies. Results: 152 (92%) of the 165 initial core biopsies were deemed to contain adequate nodal tissue. Core biopsy correctly established malignancy in 75 of the 78 patients with haematological malignancy (96%) and in all 28 patients with metastatic carcinoma (100%) and correctly diagnosed benign changes in 49 of 57 (86%) patients with benign conditions. There were no false positives and no false negatives. In 67 (85.9%) of the 78 patients with hematological malignancy, there was sufficient material in the first core biopsy to allow the pathologist to make an actionable diagnosis and not ask for more tissue sampling prior to treatment. There were no complications of core biopsy. On follow up, none of the patients with benign cores has been shown to have malignancy in the axilla and none with lymphoma had their initial disease incorrectly classified. Conclusions: This study shows that core biopsy is now the investigation of choice for patients presenting with axillary lymphadenopathy even in those suspected as having lymphoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=core%20biopsy" title="core biopsy">core biopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=excision%20biopsy" title=" excision biopsy"> excision biopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=axillary%20lymphadenopathy" title=" axillary lymphadenopathy"> axillary lymphadenopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=non-breast%20malignancy" title=" non-breast malignancy"> non-breast malignancy</a> </p> <a href="https://publications.waset.org/abstracts/141187/diagnostic-accuracy-of-core-biopsy-in-patients-presenting-with-axillary-lymphadenopathy-and-suspected-non-breast-malignancy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/141187.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">241</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">41</span> Giant Cancer Cell Formation: A Link between Cell Survival and Morphological Changes in Cancer Cells</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rostyslav%20Horbay">Rostyslav Horbay</a>, <a href="https://publications.waset.org/abstracts/search?q=Nick%20Korolis"> Nick Korolis</a>, <a href="https://publications.waset.org/abstracts/search?q=Vahid%20Anvari"> Vahid Anvari</a>, <a href="https://publications.waset.org/abstracts/search?q=Rostyslav%20Stoika"> Rostyslav Stoika</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Giant cancer cells (GCC) are common in all types of cancer, especially after poor therapy. Some specific features of such cells include ~10-fold enlargement, drug resistance, and the ability to propagate similar daughter cells. We used murine NK/Ly lymphoma, an aggressive and fast growing lymphoma model that has already shown drastic changes in GCC comparing to parental cells (chromatin condensation, nuclear fragmentation, tighter OXPHOS/cellular respiration coupling, multidrug resistance). Materials and methods: In this study, we compared morpho-functional changes of GCC that predominantly show either a cytostatic or a cytotoxic effect after treatment with drugs. We studied the effect of a combined cytostatic/cytotoxic drug treatment to determine the correlation of drug efficiency and GCC formation. Doses of G1/S-specific drug paclitaxel/PTX (G2/M-specific, 50 mg/mouse), vinblastine/VBL (50 mg/mouse), and DNA-targeting agents doxorubicin/DOX (125 ng/mouse) and cisplatin/CP (225 ng/mouse) on C57 black mice. Several tests were chosen to estimate morphological and physiological state (propidium iodide, Rhodamine-123, DAPI, JC-1, Janus Green, Giemsa staining and other), which included cell integrity, nuclear fragmentation and chromatin condensation, mitochondrial activity, and others. A single and double factor ANOVA analysis were performed to determine correlation between the criteria of applied drugs and cytomorphological changes. Results: In all cases of treatment, several morphological changes were observed (intracellular vacuolization, membrane blebbing, and interconnected mitochondrial network). A lower gain in ascites (49.97% comparing to control group) and longest lifespan (22+9 days) after tumor injection was obtained with single VBL and single DOX injections. Such ascites contained the highest number of GCC (83.7%+9.2%), lowest cell count number (72.7+31.0 mln/ml), and a strong correlation coefficient between increased mitochondrial activity and percentage of giant NK/Ly cells. A high number of viable GCC (82.1+9.2%) was observed compared to the parental forms (15.4+11.9%) indicating that GCC are more drug resistant than the parental cells. All this indicates that the giant cell formation and its ability to obtain drug resistance is an expanding field in cancer research. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ANOVA" title="ANOVA">ANOVA</a>, <a href="https://publications.waset.org/abstracts/search?q=cisplatin" title=" cisplatin"> cisplatin</a>, <a href="https://publications.waset.org/abstracts/search?q=doxorubicin" title=" doxorubicin"> doxorubicin</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20resistance" title=" drug resistance"> drug resistance</a>, <a href="https://publications.waset.org/abstracts/search?q=giant%20cancer%20cells" title=" giant cancer cells"> giant cancer cells</a>, <a href="https://publications.waset.org/abstracts/search?q=NK%2FLy%20lymphoma" title=" NK/Ly lymphoma"> NK/Ly lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=paclitaxel" title=" paclitaxel"> paclitaxel</a>, <a href="https://publications.waset.org/abstracts/search?q=vinblastine" title=" vinblastine"> vinblastine</a> </p> <a href="https://publications.waset.org/abstracts/56658/giant-cancer-cell-formation-a-link-between-cell-survival-and-morphological-changes-in-cancer-cells" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/56658.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">217</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">40</span> Assessment of Isatin as Surface Recognition Group: Design, Synthesis and Anticancer Evaluation of Hydroxamates as Novel Histone Deacetylase Inhibitors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Harish%20Rajak">Harish Rajak</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamlesh%20Raghuwanshi"> Kamlesh Raghuwanshi </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Histone deacetylase (HDAC) are promising target for cancer treatment. The panobinostat (Farydak; Novartis; approved by USFDA in 2015) and chidamide (Epidaza; Chipscreen Biosciences; approved by China FDA in 2014) are the novel HDAC inhibitors ratified for the treatment of patients with multiple myeloma and peripheral T cell lymphoma, respectively. On the other hand, two other HDAC inhibitors, Vorinostat (SAHA; approved by USFDA in 2006) and Romidepsin (FK228; approved by USFDA in 2009) are already in market for the treatment of cutaneous T-cell lymphoma. Several hydroxamic acid based HDAC inhibitors i.e., belinostat, givinostat, PCI24781 and JNJ26481585 are in clinical trials. HDAC inhibitors consist of three pharmacophoric features - an aromatic cap group, zinc binding group (ZBG) and a linker chain connecting cap group to ZBG. Herein, we report synthesis, characterization and biological evaluation of HDAC inhibitors possessing substituted isatin moiety as cap group which recognize the surface of active enzyme pocket and thiosemicarbazide moiety incorporated as linker group responsible for connecting cap group to ZBG (hydroxamic acid). Several analogues were found to inhibit HDAC and cellular proliferation of Hela cervical cancer cells with GI50 values in the micro molar range. Some of the compounds exhibited promising results in vitro antiproliferative studies. Attempts were also made to establish the structure activity relationship among synthesized HDAC inhibitors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HDAC%20inhibitors" title="HDAC inhibitors">HDAC inhibitors</a>, <a href="https://publications.waset.org/abstracts/search?q=hydroxamic%20acid%20derivatives" title=" hydroxamic acid derivatives"> hydroxamic acid derivatives</a>, <a href="https://publications.waset.org/abstracts/search?q=isatin%20derivatives" title=" isatin derivatives"> isatin derivatives</a>, <a href="https://publications.waset.org/abstracts/search?q=antiproliferative%20%09%09%09activity" title=" antiproliferative activity"> antiproliferative activity</a>, <a href="https://publications.waset.org/abstracts/search?q=docking" title=" docking"> docking</a> </p> <a href="https://publications.waset.org/abstracts/40759/assessment-of-isatin-as-surface-recognition-group-design-synthesis-and-anticancer-evaluation-of-hydroxamates-as-novel-histone-deacetylase-inhibitors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/40759.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">307</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">39</span> Clinical Applications of Amide Proton Transfer Magnetic Resonance Imaging: Detection of Brain Tumor Proliferative Activity</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fumihiro%20Ima">Fumihiro Ima</a>, <a href="https://publications.waset.org/abstracts/search?q=Shinichi%20Watanabe"> Shinichi Watanabe</a>, <a href="https://publications.waset.org/abstracts/search?q=Shingo%20Maeda"> Shingo Maeda</a>, <a href="https://publications.waset.org/abstracts/search?q=Haruna%20Imai"> Haruna Imai</a>, <a href="https://publications.waset.org/abstracts/search?q=Hiroki%20Niimi"> Hiroki Niimi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> It is important to know growth rate of brain tumors before surgery because it influences treatment planning including not only surgical resection strategy but also adjuvant therapy after surgery. Amide proton transfer (APT) imaging is an emerging molecular magnetic resonance imaging (MRI) technique based on chemical exchange saturation transfer without administration of contrast medium. The underlying assumption in APT imaging of tumors is that there is a close relationship between the proliferative activity of the tumor and mobile protein synthesis. We aimed to evaluate the diagnostic performance of APT imaging of pre-and post-treatment brain tumors. Ten patients with brain tumor underwent conventional and APT-weighted sequences on a 3.0 Tesla MRI before clinical intervention. The maximum and the minimum APT-weighted signals (APTWmax and APTWmin) in each solid tumor region were obtained and compared before and after clinical intervention. All surgical specimens were examined for histopathological diagnosis. Eight of ten patients underwent adjuvant therapy after surgery. Histopathological diagnosis was glioma in 7 patients (WHO grade 2 in 2 patients, WHO grade 3 in 3 patients and WHO grade 4 in 2 patients), meningioma WHO grade1 in 2 patients and primary lymphoma of the brain in 1 patient. High-grade gliomas showed significantly higher APTW-signals than that in low-grade gliomas. APTWmax in one huge parasagittal meningioma infiltrating into the skull bone was higher than that in glioma WHO grade 4. On the other hand, APTWmax in another convexity meningioma was the same as that in glioma WHO grade 3. Diagnosis of primary lymphoma of the brain was possible with APT imaging before pathological confirmation. APTW-signals in residual tumors decreased dramatically within one year after adjuvant therapy in all patients. APT imaging demonstrated excellent diagnostic performance for the planning of surgery and adjuvant therapy of brain tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=amides" title="amides">amides</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20resonance%20imaging" title=" magnetic resonance imaging"> magnetic resonance imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=brain%20tumors" title=" brain tumors"> brain tumors</a>, <a href="https://publications.waset.org/abstracts/search?q=cell%20proliferation" title=" cell proliferation"> cell proliferation</a> </p> <a href="https://publications.waset.org/abstracts/157244/clinical-applications-of-amide-proton-transfer-magnetic-resonance-imaging-detection-of-brain-tumor-proliferative-activity" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/157244.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">139</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">38</span> Clinical Applications of Amide Proton Transfer Magnetic Resonance Imaging: Detection of Brain Tumor Proliferative Activity</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fumihiro%20Imai">Fumihiro Imai</a>, <a href="https://publications.waset.org/abstracts/search?q=Shinichi%20Watanabe"> Shinichi Watanabe</a>, <a href="https://publications.waset.org/abstracts/search?q=Shingo%20Maeda"> Shingo Maeda</a>, <a href="https://publications.waset.org/abstracts/search?q=Haruna%20Imai"> Haruna Imai</a>, <a href="https://publications.waset.org/abstracts/search?q=Hiroki%20Niimi"> Hiroki Niimi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> It is important to know the growth rate of brain tumors before surgery because it influences treatment planning, including not only surgical resection strategy but also adjuvant therapy after surgery. Amide proton transfer (APT) imaging is an emerging molecular magnetic resonance imaging (MRI) technique based on chemical exchange saturation transfer without the administration of a contrast medium. The underlying assumption in APT imaging of tumors is that there is a close relationship between the proliferative activity of the tumor and mobile protein synthesis. We aimed to evaluate the diagnostic performance of APT imaging of pre-and post-treatment brain tumors. Ten patients with brain tumor underwent conventional and APT-weighted sequences on a 3.0 Tesla MRI before clinical intervention. The maximum and the minimum APT-weighted signals (APTWmax and APTWmin) in each solid tumor region were obtained and compared before and after a clinical intervention. All surgical specimens were examined for histopathological diagnosis. Eight of ten patients underwent adjuvant therapy after surgery. Histopathological diagnosis was glioma in 7 patients (WHO grade 2 in 2 patients, WHO grade 3 in 3 patients, and WHO grade 4 in 2 patients), meningioma WHO grade 1 in 2 patients, and primary lymphoma of the brain in 1 patient. High-grade gliomas showed significantly higher APTW signals than that low-grade gliomas. APTWmax in one huge parasagittal meningioma infiltrating into the skull bone was higher than that in glioma WHO grade 4. On the other hand, APTWmax in another convexity meningioma was the same as that in glioma WHO grade 3. Diagnosis of primary lymphoma of the brain was possible with APT imaging before pathological confirmation. APTW signals in residual tumors decreased dramatically within one year after adjuvant therapy in all patients. APT imaging demonstrated excellent diagnostic performance for the planning of surgery and adjuvant therapy of brain tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=amides" title="amides">amides</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20resonance%20imaging" title=" magnetic resonance imaging"> magnetic resonance imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=brain%20tumors" title=" brain tumors"> brain tumors</a>, <a href="https://publications.waset.org/abstracts/search?q=cell%20proliferation" title=" cell proliferation"> cell proliferation</a> </p> <a href="https://publications.waset.org/abstracts/164452/clinical-applications-of-amide-proton-transfer-magnetic-resonance-imaging-detection-of-brain-tumor-proliferative-activity" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/164452.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">86</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">37</span> Comparison with Two Clinical Cases of Plasma Cell Neoplasm by Using the Method of Capillary Electrophoresis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kai%20Pai%20Huang">Kai Pai Huang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: There are several types of plasma cell neoplasms including multiple myeloma, plasmacytoma, lymphoplasmacytic lymphoma, and monoclonal gammopathy of undetermined significance (MGUS) are found in our lab. Today, we want to compare with two cases using the method of capillary electrophoresis. Method: Serum is prepared and electrophoresis is performed at alkaline PH in a capillary using the Sebia® Capillary 2. Albumin and globulins are detected by the detector which is located in the cathode of the capillary and the signals are transformed to peaks. Serum was treated with beta-mercaptoethanol which reducing the polymerized immunoglobulin to monomer immunoglobulin to clarify two M-protein are secreted from the same plasma cell clone in bone marrow. Result: Case 1: A 78-year-old female presenting dysuria, oliguria and leg edema for several months. Laboratory data showed proteinuria, leukocytosis, results of high serum IgA and lambda light chain. A renal biopsy found amyloid fibrils in the glomerular mesangial area. Serum protein electrophoresis shows a major monoclonal peak in the β region and minor small peak in gamma region, and the immunotyping studies for serum showed two IgA/λ type. Case 2: A 55-year-old male presenting abdominal distension and low back pain for more than one month. Laboratory data showed T12 T8 compression fracture, results of high serum IgM and kappa light chain. Bone marrow aspiration showed the cells from the bone marrow are B cells with monotypic kappa chain expression. Bone marrow biopsy found this is lymphoplasmacytic lymphoma (Waldenstrom macroglobulin). Serum protein electrophoresis shows a monoclonal peak in the β region and the immunotyping studies for serum showed IgM/κ type. Conclusion: Plasma cell neoplasm can be diagnosed by many examinations. Among them, using capillary electrophoresis by a lab can separate several types of gammopathy and the quantification of a monoclonal peak can be used to evaluate the patients’ prognosis or treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=plasma%20cell%20neoplasm" title="plasma cell neoplasm">plasma cell neoplasm</a>, <a href="https://publications.waset.org/abstracts/search?q=capillary%20electrophoresis" title=" capillary electrophoresis"> capillary electrophoresis</a>, <a href="https://publications.waset.org/abstracts/search?q=serum%20protein%20electrophoresis" title=" serum protein electrophoresis"> serum protein electrophoresis</a>, <a href="https://publications.waset.org/abstracts/search?q=immunotyping" title=" immunotyping"> immunotyping</a> </p> <a href="https://publications.waset.org/abstracts/92305/comparison-with-two-clinical-cases-of-plasma-cell-neoplasm-by-using-the-method-of-capillary-electrophoresis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/92305.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">146</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">36</span> Spontaneous Tumour Lysis in Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rojith%20K.%20Balakrishnan">Rojith K. Balakrishnan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Spontaneous tumour lysis syndrome is a constellation of electrolyte abnormalities and an acute renal failure which occurs in the setting of rapid cell turnover prior to the administration of cytotoxic chemotherapy. While spontaneous tumour lysis well-described in patients with Burkitt lymphoma, it is thought to occur less commonly in patients with other hematological malignancies. We present a case of forty-year-old female who presented with features of acute renal failure, on further evaluation turned out to be a newly diagnosed acute myeloid leukemia with spontaneous tumour lysis best of our knowledge only three cases of AML with spontaneous tumour lysis has reported world wide. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=AML" title="AML">AML</a>, <a href="https://publications.waset.org/abstracts/search?q=tumour%20lysis" title=" tumour lysis"> tumour lysis</a>, <a href="https://publications.waset.org/abstracts/search?q=renal%20failure" title=" renal failure"> renal failure</a>, <a href="https://publications.waset.org/abstracts/search?q=myeloid%20leukemia" title=" myeloid leukemia"> myeloid leukemia</a> </p> <a href="https://publications.waset.org/abstracts/28705/spontaneous-tumour-lysis-in-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/28705.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">294</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">35</span> Isolation, Characterization, and Optimization of Immobilized L-Asparginase- Anticancer Enzyme from Aspergillus.Niger</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Supriya%20Chatla">Supriya Chatla</a>, <a href="https://publications.waset.org/abstracts/search?q=Anjana%20Male"> Anjana Male</a>, <a href="https://publications.waset.org/abstracts/search?q=Srikala%20Kamireddy"> Srikala Kamireddy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> L-asparaginase (E.C.3.5.1.1) is an anti-cancer enzyme that has been purified and characterized for decades to study and evaluate its anti-carcinogenic activity against Hodgkin’s lymphoma. The present investigation deals with screening, isolation and optimization of L-asparaginase giving fungal strain of soil samples from different areas of AP, India. L-Aspariginase activity was estimated on the basis of the pink color surrounding the growing colony. A total of 132 colonies were screened and isolated from different samples. Based on the zone diameter, L-asparaginase activity is determined, L- asparaginase activity is optimized at 28oc and Immobilized Aspariginase had more potency than the free enzymes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=aspariginase" title="aspariginase">aspariginase</a>, <a href="https://publications.waset.org/abstracts/search?q=anticancer%20enzyme" title=" anticancer enzyme"> anticancer enzyme</a>, <a href="https://publications.waset.org/abstracts/search?q=Isolation" title=" Isolation"> Isolation</a>, <a href="https://publications.waset.org/abstracts/search?q=optimization" title=" optimization"> optimization</a> </p> <a href="https://publications.waset.org/abstracts/161845/isolation-characterization-and-optimization-of-immobilized-l-asparginase-anticancer-enzyme-from-aspergillusniger" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/161845.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">80</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">34</span> Minimizing the Impact of Covariate Detection Limit in Logistic Regression</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shahadut%20Hossain">Shahadut Hossain</a>, <a href="https://publications.waset.org/abstracts/search?q=Jacek%20Wesolowski"> Jacek Wesolowski</a>, <a href="https://publications.waset.org/abstracts/search?q=Zahirul%20Hoque"> Zahirul Hoque</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In many epidemiological and environmental studies covariate measurements are subject to the detection limit. In most applications, covariate measurements are usually truncated from below which is known as left-truncation. Because the measuring device, which we use to measure the covariate, fails to detect values falling below the certain threshold. In regression analyses, it causes inflated bias and inaccurate mean squared error (MSE) to the estimators. This paper suggests a response-based regression calibration method to correct the deleterious impact introduced by the covariate detection limit in the estimators of the parameters of simple logistic regression model. Compared to the maximum likelihood method, the proposed method is computationally simpler, and hence easier to implement. It is robust to the violation of distributional assumption about the covariate of interest. In producing correct inference, the performance of the proposed method compared to the other competing methods has been investigated through extensive simulations. A real-life application of the method is also shown using data from a population-based case-control study of non-Hodgkin lymphoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=environmental%20exposure" title="environmental exposure">environmental exposure</a>, <a href="https://publications.waset.org/abstracts/search?q=detection%20limit" title=" detection limit"> detection limit</a>, <a href="https://publications.waset.org/abstracts/search?q=left%20truncation" title=" left truncation"> left truncation</a>, <a href="https://publications.waset.org/abstracts/search?q=bias" title=" bias"> bias</a>, <a href="https://publications.waset.org/abstracts/search?q=ad-hoc%20substitution" title=" ad-hoc substitution"> ad-hoc substitution</a> </p> <a href="https://publications.waset.org/abstracts/55567/minimizing-the-impact-of-covariate-detection-limit-in-logistic-regression" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/55567.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">236</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">33</span> Protective Effect of the Standardized Extract of Holmskioldia sanguinea on Tumor Bearing Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahesh%20Pal">Mahesh Pal</a>, <a href="https://publications.waset.org/abstracts/search?q=Tripti%20Mishra"> Tripti Mishra</a>, <a href="https://publications.waset.org/abstracts/search?q=Chandana%20Rao"> Chandana Rao</a>, <a href="https://publications.waset.org/abstracts/search?q=Dalip%20Upreti"> Dalip Upreti</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancer has been considered to be a very dreadful disease. Holmskioldia sanguinea is a large climbing shrub found in the Himalayas at an altitude of 5,000 ft and preliminary investigation showed the excellent yield of andrographolide and subjected for the anticancer activity. Protective effect of Holmskioldia sanguinea leaf ethanolic extract has been investigated against Ehrlich ascites carcinoma (EAC) and Daltons ascites lymphoma (DAL) in Swiss albino mice to evaluate the possible mechanism of action. The enzymatic antioxidant status was studied on tumor bearing mice, which shows the potential of the compound to possess significant free radical scavenging property and revealed significant tumor regression and prolonged survival time. The isolated bioactive molecule andrographolide from Holmskioldia sanguinea yields (2.5%) in subject to HPTLC/HPLC analysis. The cellular defense system constituting the superoxide dismutase, catalyses was enhanced whereby the lipid peroxidation content was restricted to a larger extent. The Holmskioldia sanguinea is a new source of andrographolide and demonstrated the potency in treatment of cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Holmskioldia%20sanguinea" title="Holmskioldia sanguinea">Holmskioldia sanguinea</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=mice" title=" mice"> mice</a>, <a href="https://publications.waset.org/abstracts/search?q=andrographolide" title=" andrographolide"> andrographolide</a> </p> <a href="https://publications.waset.org/abstracts/69400/protective-effect-of-the-standardized-extract-of-holmskioldia-sanguinea-on-tumor-bearing-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/69400.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">263</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">32</span> Bcl-2: A Molecule to Detect Oral Cancer and Precancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Vandana%20Singh">Vandana Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Subash%20Singh"> Subash Singh </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Oral squamous cell carcinoma is the most common malignant tumor of the oral cavity. Normally the death of cell and the growth are active processes and depend not only on external factors but also on the expression of genes like Bcl-2, which activate and inhibit apoptosis. The term Bcl-2 is an acronym for B-cell lymphoma/ leukemia -2 genes. Objectives: An attempt was made to evaluate Bcl-2 oncoprotein expression in patients with oral precancer and cancer and to assess possible correlation between Bcl-2 oncoprotein expression and clinicopathological features of oral precancer and cancer. Material and Methods: This is a selective prospective clinical and immunohistochemical study. Clinicopathological examination is correlated with immunohistochemical findings. The immunolocalization of Bcl-2 protein is performed using the labeled streptavidin biotin (LSAB) method. To visualize the reaction, 3, 3-diaminobenzidine (DAB) is used. Results: Bcl-2 expression was positive in 11 [36.66 %, low Bcl-2 expression 3 (10.00 %), moderate Bcl-2 expression 7 (23.33 %), and high Bcl-2 expression 1 (3.33 %)] oral cancer cases and in 14 [87.50 %, low expression 8 (50 %), moderate expression 6 (37.50 %)] precancer cases. Conclusion: On the basis of the results of our study we conclude that positive Bcl-2 expression may be an indicator of poor prognosis in oral cancer and precancer. Relevance: It has been reported that there is deregulation of Bcl-2 expression during progression from oral epithelial dysplasia to squamous cell carcinoma. It can be used for revealing progression of epithelial dysplasia to malignancy and as a prognostic marker in oral precancer and cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BcL-2" title="BcL-2">BcL-2</a>, <a href="https://publications.waset.org/abstracts/search?q=immunohistochemistry" title=" immunohistochemistry"> immunohistochemistry</a>, <a href="https://publications.waset.org/abstracts/search?q=oral%20cancer" title=" oral cancer"> oral cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=oral%20precancer" title=" oral precancer"> oral precancer</a> </p> <a href="https://publications.waset.org/abstracts/79418/bcl-2-a-molecule-to-detect-oral-cancer-and-precancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/79418.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">269</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">31</span> Meningeal Hemangiopericytoma in an HIV-Positive Patient: A Case Report and Review of Literature</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Roland%20Benedict%20Reyes">Roland Benedict Reyes</a>, <a href="https://publications.waset.org/abstracts/search?q=Marc%20Edsel%20Ayes"> Marc Edsel Ayes</a>, <a href="https://publications.waset.org/abstracts/search?q=Regina%20Berba"> Regina Berba</a>, <a href="https://publications.waset.org/abstracts/search?q=Cybele%20Lara%20Abad"> Cybele Lara Abad</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Three AIDS-defining malignancies have been associated with the human immunodeficiency virus (HIV): Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical carcinoma. However, new cases of non-AIDS defining malignancies also have been increasingly associated with HIV. One of these is a rare intracranial malignancy, meningeal hemangiopericyotma. Case Description: A 32-year old HIV-positive male, not on highly active antiretroviral therapy, was admitted to our hospital due to generalized weakness and sudden onset hearing loss. Cranial MRI was done, which revealed a temporal nodule with the following considerations: granuloma, meningioma or metastases. A craniotomy was performed and the mass excised. Results from the biopsy showed meningeal hemangiopericytoma. The patient was then started on antiretroviral therapy (Lamivudine, Tenofovir, and Efavirenz) and was discharged for radiation therapy and metastatic work-up as an outpatient. On follow-up seven months later, metastatic work up revealed multiple hepatic foci not previously documented suggestive of metastasis short of biopsy sampling. Conclusions: This case of an intracranial hemangiopericytoma in an HIV-positive patient is the second case thus far presented, based on our systematic and extensive search of the literature. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hemangiopericytoma" title="Hemangiopericytoma">Hemangiopericytoma</a>, <a href="https://publications.waset.org/abstracts/search?q=Human%20Immunodeficiency%20Virus" title=" Human Immunodeficiency Virus"> Human Immunodeficiency Virus</a>, <a href="https://publications.waset.org/abstracts/search?q=Meningeal%20hemangiopericytoma" title=" Meningeal hemangiopericytoma"> Meningeal hemangiopericytoma</a>, <a href="https://publications.waset.org/abstracts/search?q=Neoplasm" title="Neoplasm">Neoplasm</a> </p> <a href="https://publications.waset.org/abstracts/22857/meningeal-hemangiopericytoma-in-an-hiv-positive-patient-a-case-report-and-review-of-literature" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/22857.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">463</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">30</span> The Regulation of the Pro-inflammatory Cytokine Interleukin 6 (IL6) by Epstein-Barr Virus (EBV)</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Liu%20Xiaohan">Liu Xiaohan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Epstein–Barr virus (EBV) is a human herpesvirus and is closely related to many malignancies of lymphocyte and epithelial origins, such as gastric cancer, Burkitt’s lymphoma, and nasopharyngeal carcinoma (NPC). NPC is a malignant epithelial tumor which is 100% associated with EBV latent infection. Most of the NPC cases are densely populated in southern China, especially in Guangdong and Hong Kong. To our knowledge, overexpression of pro-inflammatory cytokines may result in a loss of balance of the immune system and cause damage to human bodies. Interleukin-6 (IL6) is a pro-inflammatory cytokine which plays an important role in tumor progression. In addition, gene expression is regulated by both transcriptional and post-transcriptional pathways, while post-transcriptional regulation is an important mechanism to modulate the mature mRNA level in mammalian cells. AU-rich element binding factor 1 (AUF1)/heterogeneous nuclear RNP D (hnRNP D) is known for its function in destabilizing mRNAs, including cytokines and cell cycle regulators. Previous studies have found that overexpression of hnRNP D would lead to tumorigenesis. In this project, our aim is to determine the role played by hnRNP D in EBV-infected cells and how our anti-EBV agents can affect the function of hnRNP D. The results of this study will provide a new insight into how the pro-inflammatory cytokine expression can be regulated by EBV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=interleukin%206%20%28IL6%29" title="interleukin 6 (IL6)">interleukin 6 (IL6)</a>, <a href="https://publications.waset.org/abstracts/search?q=epstein-barr%20virus%20%28EBV%29" title=" epstein-barr virus (EBV)"> epstein-barr virus (EBV)</a>, <a href="https://publications.waset.org/abstracts/search?q=nasopharyngeal%20carcinoma%20%28NPC" title=" nasopharyngeal carcinoma (NPC"> nasopharyngeal carcinoma (NPC</a>, <a href="https://publications.waset.org/abstracts/search?q=epstein-barr%20nuclear%20antigen-1%20%28EBNA1%29" title=" epstein-barr nuclear antigen-1 (EBNA1)"> epstein-barr nuclear antigen-1 (EBNA1)</a> </p> <a href="https://publications.waset.org/abstracts/173829/the-regulation-of-the-pro-inflammatory-cytokine-interleukin-6-il6-by-epstein-barr-virus-ebv" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/173829.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">62</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">29</span> Collision Tumor of Plasmacytoma with Hematological and Non-Hematological Malignancies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arati%20Inamdar">Arati Inamdar</a>, <a href="https://publications.waset.org/abstracts/search?q=Siddharth%20Bhattacharyya"> Siddharth Bhattacharyya</a>, <a href="https://publications.waset.org/abstracts/search?q=Kester%20Haye"> Kester Haye</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Collision tumors are rare entities characterized by neoplasms of two different cell populations with distinct separating boundaries. Such tumors could be benign, malignant, or a combination of both. The exact mechanism of origin for collision tumors is predicted to be tumor heterogeneity or concurrent occurrence of neoplasm in the same organ. We present two cases of plasmacytoma presenting as a collision tumor, one with a tumor of hematological origin and another with a non-hematological origin, namely Chronic Lymphocytic Leukemia and Adenocarcinoma of the colon, respectively. The immunohistochemical stains and flowcytometry analysis performed on the specimens aided incorrect diagnosis. Interestingly, neoplastic cells of plasmacytoma in the first case demonstrated strong cytokeratin along with weak Epithelial Specific Antigen/ Epithelial cell adhesion molecule Monoclonal Antibody (MOC31) positivity, indicating that the tumor may influence the microenvironment of the tumor in the vicinity. Furthermore, the next-generation sequencing studies performed on the specimen with plasmacytoma and chronic lymphocytic lymphoma demonstrated BReast CAncer gene (BRCA2) and Tumor Necrosis Factor Alpha Induced Protein 3 (TNFAIP3) as a disease associated variants suggestive of risk for multiple tumors including collision tumors. Our reports highlight the unique collision tumors involving plasmacytoma, which have never been reported previously, as well as provide necessary insights about the underline genetic aberrations and tumor heterogeneity through sequencing studies and allow clonality assessment for subsequent tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BRCA2" title="BRCA2">BRCA2</a>, <a href="https://publications.waset.org/abstracts/search?q=collision%20tumor" title=" collision tumor"> collision tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20lymphocytic%20leukemia" title=" chronic lymphocytic leukemia"> chronic lymphocytic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=plasmacytoma" title=" plasmacytoma"> plasmacytoma</a> </p> <a href="https://publications.waset.org/abstracts/162721/collision-tumor-of-plasmacytoma-with-hematological-and-non-hematological-malignancies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/162721.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">189</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=NK%2FLy%20lymphoma&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=NK%2FLy%20lymphoma&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>